Pharmaceutical company GlaxoSmithKline (NYSE: GSK ) recently gained approval for two cancer drugs --- Mekinist and Tafinlar --- but the Food and Drug Administration recently announced that a combination treatment consisting of these two drugs has been given priority review status. In the following video from The Motley Fool's show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the details behind this news and the potential impact on GlaxoSmithKline's business.
Cash in on big pharma
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The relevant video segment can be found between 3:25-6:01.